Skip to main content
SpringerLink
Log in

Hyperandrogenism and Polycystic Ovarian Disease: Impact on Vascular System

  • Reference work entry
  • First Online:
PanVascular Medicine

  • 134 Accesses

Abstract

The 2003 Rotterdam consensus workshop concluded that polycystic ovarian syndrome (PCOS) is an ovarian dysfunction with hyperandrogenism and polycystic ovary (PCO) morphology. Therefore, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis (Rotterdam Group, 2004). PCOS is characterized by hyperandrogenism, anovulation, and an increased incidence of type 2 diabetes mellitus, insulin resistance, and coronary artery disease in mid-adult life. Women with PCOS have a higher risk of metabolic syndrome and its cardiovascular sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

IGFs:

Insulin-like growth factors

PAI-1:

Plasminogen activator inhibitor type I

PCOS:

Polycystic ovarian syndrome

References

  • Amowitz LL, Sobel BE (1999) Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28:439–458

    Article  CAS  PubMed  Google Scholar 

  • Atkin SL (2013) Cardiovascular disease in polycystic ovary syndrome. Clin Endocrinol (Oxf) 78:823–824

    Article  CAS  Google Scholar 

  • Bonadonna RC (1999) Insulin as a vascular hormone. Pract Diab Int 16(Suppl):S15–S18

    Google Scholar 

  • Boyle J, Teede HJ (2012) Polycystic ovary syndrome, an update. Aust Fam Physician 41:752–756

    PubMed  Google Scholar 

  • Broekmans FJ, Fauser BC (2006) Diagnostic criteria for polycystic ovarian syndrome. Endocrine 30:3–11

    Article  CAS  PubMed  Google Scholar 

  • Chang RJ, Katz SE (1999) Diagnosis of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28:397–408

    Article  CAS  PubMed  Google Scholar 

  • Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S, Meade TW (1992) How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol (Oxf) 37:127–134

    Article  CAS  Google Scholar 

  • Culiner A, Shippel S (1949) Virilism and theca cell hyperplasia of the ovary syndrome. J Obstet Gynaecol Br Commonw 56:439–445

    Article  CAS  Google Scholar 

  • Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Odén A, Janson PO, Mattson LA, Crona N, Lundberg PA (1992) Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focussing on natural history and circulating hormones. Fertil Steril 57:505–513

    Article  CAS  PubMed  Google Scholar 

  • DeFronzo R, Brazilai N, Simonson D (1991) Mechanisms of metformin action in obese and lean non-insulin dependent diabetic subjects. J Clin Endocrinol Metab 73:1294–1301

    Article  CAS  PubMed  Google Scholar 

  • Du Q, Wang YJ, Yang S, Wu B, Han P, Zhao YY (2012) A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 28:723–730

    Article  CAS  PubMed  Google Scholar 

  • Fantus I, Brosseau R (1986) Mechanism of action of metformin: insulin receptor and post receptor effects in vitro and in vivo. J Clin Endocrinol Metab 63:898–905

    Article  CAS  PubMed  Google Scholar 

  • Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT (1994) The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust NZ J Obstet Gynecol 34:67–72

    Article  CAS  Google Scholar 

  • Graf MJ, Richards CJ, Brown V, Meissner L, Dunaif A (1990) The independent effects of hyperandrogenaemia, hyperinsulinaemia and obesity on lipid and lipoprotein profiles in women. Clin Endocrinol (Oxf) 33:119–131

    Article  CAS  Google Scholar 

  • Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr (1994) Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case control study. Am J Obstet Gynecol 74:1224–1229

    Google Scholar 

  • Holte J, Bergh T, Berne C, Wide L, Lithell H (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:2586–2593

    CAS  PubMed  Google Scholar 

  • Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR (1990) Fibrinogen and the risk of cardiovascular disease: the Framingham experience. Am Heart J 120:672–676

    Article  CAS  PubMed  Google Scholar 

  • Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY, Yang SY, Zhang SH (2011) Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf) 74:332–339

    Article  CAS  Google Scholar 

  • Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH (1996) A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 322:882–889

    Article  Google Scholar 

  • Mitka M (2013) Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. JAMA 310:246–247

    Article  CAS  PubMed  Google Scholar 

  • Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I (2013) Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine 44(3):583–590

    Article  CAS  PubMed  Google Scholar 

  • Pasquale R, Casmirri F (1994) Body fat distribution has weight independent effects on clinical, hormonal and metabolic features in women with polycystic ovary syndrome. Metabolism 43:706–713

    Article  Google Scholar 

  • Pasquali R, Gambineri A (2013) Insulin sensitizers in polycystic ovary syndrome. Front Horm Res 40:83–102

    Article  CAS  PubMed  Google Scholar 

  • Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767–2774

    Article  CAS  PubMed  Google Scholar 

  • Psaty BM, Furberg CD (2007) Rosiglitazone and cardiovascular risk. N Engl J Med 356:2522–2524

    Article  CAS  PubMed  Google Scholar 

  • Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607

    Article  CAS  PubMed  Google Scholar 

  • Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE (1995) The primary prevention of coronary heart disease in women. N Engl J Med 332:1758–1766

    Article  CAS  PubMed  Google Scholar 

  • Schneider DJ, Ricci MA, Taatjes DJ, Baumann PQ, Reese JC, Leavitt BJ, Absher PM, Sobel BE (1997) Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol 17:3294–3301

    Article  CAS  PubMed  Google Scholar 

  • Solorzano BCM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC (2012) Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 77:332–337

    Article  Google Scholar 

  • Stankiewicz M, Norman R (2006) Diagnosis and management of polycystic ovary syndrome: a practical guide. Drugs 66:903–912

    Article  PubMed  Google Scholar 

  • Stehouwer CDA (1999) Insulin resistance and hypertension. Pract Diab Int 16(Suppl):S19–S21

    Google Scholar 

  • Stubbs SA, Webber LJ, Stark J, Rice S, Margara R, Lavery S, Trew GH, Hardy K, Franks S (2013) Role of insulin-like growth factors in initiation of follicle growth in normal and polycystic human ovaries. J Clin Endocrinol Metab 98:3298–3305

    Article  CAS  PubMed  Google Scholar 

  • Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821–826

    Article  CAS  PubMed  Google Scholar 

  • Wenger NK, Speroff L, Packard B (1993) Cardiovascular health and disease in women. N Engl J Med 329:247–256

    Article  CAS  PubMed  Google Scholar 

  • Wild RA (1997) Metabolic aspects of polycystic ovary syndrome. Semin Reprod Endocrinol 15:105–110

    Article  CAS  PubMed  Google Scholar 

Further Reading

  • Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. Diabetes 38:1165–1174

    Article  CAS  PubMed  Google Scholar 

  • Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257–1266

    Article  CAS  PubMed  Google Scholar 

  • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology/Medicine Department, Hospital de Sant Pau, IIB-SantPau, CIBERER 747, Universitat Autònoma de Barcelona, Pare Claret 167, 08025, Barcelona, Spain

    Eugenia Resmini

  2. Gynecolgy/Medicine Department, Fundació Puigvert, Universitat Autònoma de Barcelona, Cartagena 340-350, 08025, Barcelona, Spain

    Mónica González Fernández

Authors
  1. Eugenia Resmini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mónica González Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eugenia Resmini .

Editor information

Editors and Affiliations

  1. Division of Cardiovascular Disease Department of Internal Medicine, Health Care Center Bitterfeld, Bitterfeld-Wolfen, Germany

    Peter Lanzer

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Resmini, E., González Fernández, M. (2015). Hyperandrogenism and Polycystic Ovarian Disease: Impact on Vascular System. In: Lanzer, P. (eds) PanVascular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37078-6_171

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37078-6_171

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37077-9

  • Online ISBN: 978-3-642-37078-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation